Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor C...( PRINCETON N.J. Sept. 5 /- Pharmas...)

PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the 3rd Annual Citi Biotech Day being held September 8, 2008, at the Citi Executive Conference Center, New York, NY. Management will also present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008, at the Grand Hyatt Hotel, New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide a brief overview of the company followed by a question and answer session at both conferences.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer